You are not currently logged in.
Access JSTOR through your library or other institution:
Economic Impact of Ventilator-Associated Pneumonia in a Large Matched Cohort
Marin H. Kollef MD, Cindy W. Hamilton PharmD and Frank R. Ernst PharmD MS
Infection Control and Hospital Epidemiology
Vol. 33, No. 3 (March 2012), pp. 250-256
Published by: Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Stable URL: http://www.jstor.org/stable/10.1086/664049
Page Count: 7
You can always find the topics here!Topics: Hospital costs, Intensive care units, Health care costs, Mortality, Operating rooms, Artificial respiration, Hospitalization, Ventilator associated pneumonia, Economic costs, Unit costs
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Objective. To evaluate the economic impact of ventilator-associated pneumonia (VAP) on length of stay and hospital costs.Design. Retrospective matched cohort study.Setting. Premier database of hospitals in the United States.Patients. Eligible patients were admitted to intensive care units (ICUs), received mechanical ventilation for ≥2 calendar-days, and were discharged between October 1, 2008, and December 31, 2009.Methods. VAP was defined by International Classification of Diseases, Ninth Revision (ICD-9), code 997.31 and ventilation charges for ≥2 calendar-days. We matched patients with VAP to patients without VAP by propensity score on the basis of demographics, administrative data, and severity of illness. Cost was based on provider perspective and procedural cost accounting methods.Results. Of 88,689 eligible patients, 2,238 (2.5%) had VAP; the incidence rate was 1.27 per 1,000 ventilation-days. In the matched cohort, patients with VAP () had longer mean durations of mechanical ventilation (21.8 vs 10.3 days), ICU stay (20.5 vs 11.6 days), and hospitalization (32.6 vs 19.5 days; all ) than patients without VAP (). Mean hospitalization costs were $99,598 for patients with VAP and $59,770 for patients without VAP (), resulting in an absolute difference of $39,828. Patients with VAP had a lower in-hospital mortality rate than patients without VAP (482/2,144 [22.5%] vs 630/2,144 [29.4%]; ).Conclusions. Our findings suggest that VAP continues to occur as defined by the new specific ICD-9 code and is associated with a statistically significant resource utilization burden, which underscores the need for cost-effective interventions to minimize the occurrence of this complication.
© 2012 by The Society for Healthcare Epidemiology of America. All rights reserved.